한국임상약학회지 (Korean Journal of Clinical Pharmacy)

  • 제21권3호
  • /
  • Pages.270-275
  • /
  • 2011
  • /
  • 1226-6051(pISSN)
  • /
  • 2508-786X(eISSN)
한국임상약학회 (Korean College Of Clinical Pharmacy)
권호 표지

Warfarin과 Simvastatin/Gemfibrozil의 약물 상호 작용 : 높은 수치의 ALT/AST, 횡문근 융해와 급성 신장 장애

Drug Interaction of Warfarin with Simvastatin / Gemfibrozil : high levels of ALT/AST, rhabdomyolysis and acute renal failure

  • 윤현옥 (미국 하워드 대학교 약학대학) ;
  • 투고 : 2011.07.20
  • 심사 : 2011.08.11
  • 발행 : 2011.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

이 증례는 드물게 보는 경우로 simvastatin과 gemfibrozil을 오랫동안 함께 복용했음에도, 특이한 문제가 발현되지 않았지만, 이들을 warfarin와 함께 치료하는 경우, 아주 높은 alanine aminotransferase (ALT), aspartate aminotransferase(AST) 혈중 농도, rhabdomyolysis, 급성 신장 장애가 발생하였다. 그 후, Simvastatin와 gemfibrozil을 복용 중단시켰더니, ALT/AST는 빠르게 정상수치로 돌아온 경우이다. 이 증례 보고서는 의료인들에게 simvastatin과 gemfibrozil을 함께 혹은 따로 warfarin과 함께 복용시켜 치료할 경우, creatine phosphokinase (CPK) 와 creatinine 혈중 수치들을 포함하여 ALT/AST 농도들을 주의 깊게 모니터하도록 경각심을 주고자 한다.

키워드

참고문헌

  1. Mol MJ, Stuyt PM, Stalenhoef AF, van 't Laar A. Cholesterol synthesis inhibitors in hyperlipidaemia. Lancet 1988; 1: 597.
  2. Schulzeck P, Bojanovski M, Jochim A, Canzler H, Bojanovski D. Comparison between simvastatin and bezafibrate in effect on plasma lipoproteins and apolipoproteins in primary hypercholesterolaemia. Lancet 1988; 1: 611-3.
  3. Bard JM, Luc G, Douste-Blazy P, et al., Effect of simvastatin on plasma lipids, apolipoproteins and lipoprotein particles in patients with primary hypercholesterolaemia. Eur J Clin Pharmacol 1989; 37: 545-50. https://doi.org/10.1007/BF00562541
  4. Boccuzzi SJ, Bocanegra TS, Walker JF, Shapiro DR, Keegan ME. Long-term safety and efficacy profile of simvastatin. Am J Cardiol 1991; 68: 1127-31. https://doi.org/10.1016/0002-9149(91)90182-K
  5. Ayanian JZ, Fuchs CS, Stone RM. Lovastatin and rhabdomyolysis. Ann Intern Med 1988; 109 :682-3. https://doi.org/10.7326/0003-4819-109-8-682
  6. Corpier CL, Jones PH, Suki WN, et al., Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients. Jama 1988; 260: 239-41. https://doi.org/10.1001/jama.1988.03410020105038
  7. Jacobson RH, Wang P, Glueck CJ. Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone. Jama 1997; 277: 296-7.
  8. Lees RS, Lees AM. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N Engl J Med 1995; 333: 664-5. https://doi.org/10.1056/NEJM199509073331015
  9. Schmassmann-Suhijar D, Bullingham R, Gasser R, Schmutz J, Haefeli WE. Rhabdomyolysis due to interaction of simvastatin with mibefradil. Lancet 1998; 351: 1929-30. https://doi.org/10.1016/S0140-6736(05)78613-X
  10. Becquemont L. [Drug interactions with antilipemics]. Therapie 2003; 58: 85-90. https://doi.org/10.2515/therapie:2003012
  11. Capone D, Stanziale P, Gentile A, Imperatore P, Pellegrino T, Basile V. Effects of simvastatin and pravastatin on hyperlipidemia and cyclosporin blood levels in renal transplant recipients. Am J Nephrol 1999; 19: 411-5. https://doi.org/10.1159/000013487
  12. Ohno Y, Hisaka A, Suzuki H. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Clin Pharmacokinet 2007; 46: 681-96. https://doi.org/10.2165/00003088-200746080-00005
  13. Fenneteau F, Poulin P, Nekka F. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates. J Pharm Sci; 99: 486-514.
  14. Yeo KR, Yeo WW. Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes. Br J Clin Pharmacol 2001; 51: 461-70.
  15. Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 2003;63: 769-802. https://doi.org/10.2165/00003495-200363080-00004
  16. Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol; 32: 675-703.
  17. Olsson AG, Rossner S, Walldius G, Carlson LA. Effect of gemfibrozil on lipoprotein concentrations in different types of hyperlipoproteinaemia. Proc R Soc Med 1976; 69 Suppl 2: 28-31.
  18. Betteridge DJ, Higgins MJ, Galton DJ. Properties of sterol biosynthesis in human leukocytes: effects of gemfibrozil. Proc R Soc Med 1976; 69 Suppl 2: 104-6.
  19. Knoll RW, Ciafone R, Galen M. Rhabdomyolysis and renal failure secondary to combination therapy of hyperlipidemia with lovastatin and gemfibozil. Conn Med 1993; 57: 593-4.
  20. Armitage J, Bowman L, Wallendszus K, et al., Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet; 376: 1658-69.
  21. Chang JT, Staffa JA, Parks M, Green L. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf 2004; 13: 417-26. https://doi.org/10.1002/pds.977
  22. Backman JT, Kyrklund C, Kivisto KT, Wang JS, Neuvonen PJ. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 2000; 68: 122-9. https://doi.org/10.1067/mcp.2000.108507
  23. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006; 80: 565-81. https://doi.org/10.1016/j.clpt.2006.09.003
  24. Prueksaritanont T, Ma B, Yu N. The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. Br J Clin Pharmacol 2003; 56: 120-4. https://doi.org/10.1046/j.1365-2125.2003.01833.x
  25. Franson JC. Enzyme activities in plasma, liver and kidney of black ducks and mallards. J Wildl Dis 1982;18: 481-5. https://doi.org/10.7589/0090-3558-18.4.481
  26. Dianzani MU. [Distribution of lactic acid oxidase in liver and kidney cells of normal rats and rats with fatty degeneration of the liver]. Arch Fisiol 1951 ;50 :181-6.
  27. Barchetta I, Angelico F, Del Ben M, et al., Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. BMC Med; 9: 85.
  28. Figueroa RB, Klotz AP. The Effect of Whiskey and Low-Protein Diets on Hepatic Enzymes in Rats. Am J Dig Dis 1964; 9 :121-7. https://doi.org/10.1007/BF02243515
  29. Hofmann AF, Korman MG, Krugman S. Sensitivity of serum bile acid assay for detection of liver damage in viral hepatitis type B. Prospective study in five patients. Am J Dig Dis 1974; 19 :908-10. https://doi.org/10.1007/BF01076213
  30. Hickmott H, Wynne H, Kamali F. The effect of simvastatin co-medication on warfarin anticoagulation response and dose requirements. Thromb Haemost 2003; 89: 949-50.
  31. Keech A, Collins R, MacMahon S, et al., Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. Eur Heart J 1994; 15: 255-69. https://doi.org/10.1093/eurheartj/15.suppl_3.255
  32. Gaw A, Wosornu D. Simvastatin during warfarin therapy in hyperlipoproteinaemia. Lancet 1992; 340: 979-80.
  33. Ahmad S. Gemfibrozil interaction with warfarin sodium (coumadin). Chest 1990; 98: 1041-2.
  34. Dixon DL, Williams VG. Interaction between gemfibrozil and warfarin: case report and review of the literature. Pharmacotherapy 2009; 29: 744-8. https://doi.org/10.1592/phco.29.6.744
  35. Mogyorosi A, Bradley B, Showalter A, Schubert ML. Rhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarin. J Intern Med 1999; 246: 599-602. https://doi.org/10.1046/j.1365-2796.1999.00610.x